The specific objective of this contract will be to provide the Investigational Drug Branch (IDB), CTEP, DCT, NCI, with Phase I clinical evaluations of investigational new drugs which are developed through the DCT Linear Array and are sponsored to the Food and Drug Administration (FDA) under an IND held by DCT. The objective of Phase I studies is to provide the parameters and characteristics of drug toxicity, the maximally tolerated dose, and a recommended Phase II dose.
| Trump, D L; Tutsch, K D; Willson, J K et al. (1987) Phase I clinical trial and pharmacokinetic evaluation of acodazole (NSC 305884), an imidazoquinoline derivative with electrophysiological effects on the heart. Cancer Res 47:3895-900 |
| Trump, D L; Grem, J L; Tutsch, K D et al. (1987) Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol 5:1281-9 |
| Grem, J L; Tutsch, K D; Simon, K J et al. (1987) Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 71:1179-84 |
| Koeller, J M; Trump, D L; Tutsch, K D et al. (1986) Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer 57:222-5 |
| Benson 3rd, A B; Trump, D L; Koeller, J M et al. (1985) Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep 69:795-9 |
